CA2993614A1 - Combination therapy using acamprosate and d-cycloserine - Google Patents

Combination therapy using acamprosate and d-cycloserine Download PDF

Info

Publication number
CA2993614A1
CA2993614A1 CA2993614A CA2993614A CA2993614A1 CA 2993614 A1 CA2993614 A1 CA 2993614A1 CA 2993614 A CA2993614 A CA 2993614A CA 2993614 A CA2993614 A CA 2993614A CA 2993614 A1 CA2993614 A1 CA 2993614A1
Authority
CA
Canada
Prior art keywords
cycloserine
administered
therapeutic agent
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2993614A
Other languages
English (en)
French (fr)
Inventor
Steven L. Johns
Craig A. Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Confluence Pharmaceuticals LLC
Original Assignee
Confluence Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals LLC filed Critical Confluence Pharmaceuticals LLC
Publication of CA2993614A1 publication Critical patent/CA2993614A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2993614A 2015-08-04 2016-08-04 Combination therapy using acamprosate and d-cycloserine Abandoned CA2993614A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200864P 2015-08-04 2015-08-04
US62/200,864 2015-08-04
PCT/US2016/045547 WO2017024129A1 (en) 2015-08-04 2016-08-04 Combination therapy using acamprosate and d-cycloserine

Publications (1)

Publication Number Publication Date
CA2993614A1 true CA2993614A1 (en) 2017-02-09

Family

ID=57944041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2993614A Abandoned CA2993614A1 (en) 2015-08-04 2016-08-04 Combination therapy using acamprosate and d-cycloserine

Country Status (11)

Country Link
US (2) US20180221315A1 (https=)
EP (1) EP3331518A4 (https=)
JP (2) JP2018526345A (https=)
KR (1) KR20180034442A (https=)
AU (2) AU2016303610A1 (https=)
CA (1) CA2993614A1 (https=)
HK (1) HK1255584A1 (https=)
IL (1) IL257035A (https=)
SG (1) SG10201914045QA (https=)
WO (1) WO2017024129A1 (https=)
ZA (1) ZA201800558B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024129A1 (en) * 2015-08-04 2017-02-09 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and d-cycloserine
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
CA3064846A1 (en) 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
JP2025069475A (ja) * 2022-03-08 2025-05-01 ソシウム株式会社 Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤
EP4702978A1 (en) * 2023-04-27 2026-03-04 Socium Inc. Agent for treating or preventing amyotrophic lateral sclerosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2010532331A (ja) * 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
HRP20150120T1 (hr) * 2009-02-12 2015-05-08 Indiana University Research And Technology Corporation Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam
WO2010099217A1 (en) * 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5893135B2 (ja) * 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
WO2017024129A1 (en) * 2015-08-04 2017-02-09 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and d-cycloserine

Also Published As

Publication number Publication date
US20180221315A1 (en) 2018-08-09
SG10201914045QA (en) 2020-03-30
EP3331518A4 (en) 2019-04-03
EP3331518A1 (en) 2018-06-13
AU2022202218A1 (en) 2022-04-21
JP2018526345A (ja) 2018-09-13
JP2021152060A (ja) 2021-09-30
WO2017024129A1 (en) 2017-02-09
IL257035A (en) 2018-03-29
AU2016303610A1 (en) 2018-02-01
KR20180034442A (ko) 2018-04-04
HK1255584A1 (zh) 2019-08-23
ZA201800558B (en) 2019-10-30
US20200360316A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
AU2022202218A1 (en) Combination Therapy Using Acamprosate And D-Cycloserine
JP2023171776A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2002539245A5 (https=)
JP5864819B2 (ja) 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
KR20140146207A (ko) 운동 장애의 개선된 관리에 적합한 경구로 이용 가능한 약학적 제형
US20130190275A1 (en) Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
JP2023524039A (ja) Ｔ型カルシウムチャネルモジュレーターを使用する方法
JP7737427B2 (ja) フペルジンの放出調節医薬組成物およびその使用方法
JP2008500287A (ja) 経口供給系
RU2509560C1 (ru) Новые терапевтические комбинации миртазапина для применения при болевых расстройствах
EP4478887A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
ES3031676T3 (en) Use of higher doses of modified release huperzine formulations
JP2009511606A (ja) エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
JP2021530568A5 (https=)
JP2014530249A5 (https=)
RU2590978C1 (ru) Капсулированный препарат для лечения простуды и способ его получения
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
JP2010174028A (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
ES2863402T3 (es) Combinación de plantas oficinales y su uso en el tratamiento y/o prevención de trastornos del sueño
EP4559463A1 (en) Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders
Mentazac Almuriva (UK); Altigmin (Turkey); Alzerta (Spain); Alzest (UK); Alzigmine (Israel).• Balaxon (Greece); Begusin (Poland).
RS54912B1 (sr) Farmaceutske formulacije tiokolhikozida sa produženim oslobađanjem
JP2013028647A (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210803

FZDE Discontinued

Effective date: 20240123